Latest news with #Quibim
Telegraph
a day ago
- Health
- Telegraph
NHS to pilot AI prostate cancer tests
An AI tool to spot prostate cancer earlier is being piloted by the NHS. The two-year scheme involving more than 3,000 men aims to speed up diagnosis of the disease, which is the most common form of cancer in men. Every year around 55,000 men in the UK are diagnosed with prostate cancer and 12,000 die from it. But just half of cases are caught at an early stage, when treatment is most effective. Trials suggest the technology can help radiologists detect around 11 per cent more early-stage cancers by highlighting suspicious regions in MRI scans. The software by Quibim uses advanced AI, trained on real pathology results, to segment the prostate into zones and highlight areas most likely to contain aggressive disease. The two-year pilot, backed by £2.6 million in NHS funding, will be rolled out to seven hospitals in England. Clinical trials suggest it can raise detection rates from 80 per cent to more than 90 per cent. Early detection dramatically improves survival rates. Almost all men who are diagnosed with stage one or two of the disease are alive five years later, compared with rates of less than 50 per cent for those with late-stage disease. As well as looking at detection rates, the pilot will examine the cost-effectiveness of the approach to see if the NHS can save money by catching the disease sooner. It will also examine the impact on inequalities in heath, with black men twice as likely to get prostate cancer. Prof Peter Johnson, national clinical director for cancer at NHS England, said: 'The NHS is funding and testing this exciting AI technology to help us diagnose and treat prostate cancer patients as quickly as possible and offer them the best chance of survival. 'As part of the 10-Year Health Plan, the NHS is taking advantage of our unique position to test state-of-the-art technology like this, and rolling it out as fast as we can to make the NHS fit for the future.' Dr. Ángel Alberich-Bayarri, chief executive of Quibim said: 'This NHS rollout is a major milestone in our mission to improve cancer diagnostics through AI. 'We're proud to support the NHS in advancing early detection and addressing health inequalities in prostate cancer care. By empowering radiologists with AI, we can help ensure more men are diagnosed earlier, when their chances of survival are highest.' Screening could cut deaths by 40 per cent The findings come as The Telegraph launches a campaign calling for the introduction of targeted screening for prostate cancer. Currently, men are not offered tests, even if they have a family history of the disease. Experts believe there is a growing case for targeted screening, meaning that PSA blood tests would be offered to those at heightened risk of the disease. Even though prostate cancer is the most-common male cancer in the UK, it is the only major cancer with no screening programme. The UK National Screening Committee (UKNSC) is currently considering whether to recommend the rollout of testing. In the past, it has rejected the idea because of concern that PSA tests are too unreliable, and would result in too many men undergoing needless procedures. In recent years, however, the back-up technology used to confirm a diagnosis has significantly improved, with hopes that further advances being tested, could mean that in the future, screening could cut deaths by 40 per cent. Prof Shonit Punwani, Professor of magnetic resonance and cancer imaging and consultant radiologist at UCLH, said: 'Initial studies have shown that the tool helps radiologists to enhance their diagnostic accuracy through identifying subtle early stage lesions that are sometimes not obvious on scans. 'Ultimately, QP-Prostate aims to improve patient outcomes by assisting radiologists in creating more accurate and reliable MRI reports.'
Time Business News
30-06-2025
- Health
- Time Business News
AI‑QUAL: The New AI Tool That Makes Prostate MRI Scans More Accurate
Clear medical scans help doctors see what's happening inside the body. But sometimes, these scans turn out blurry or unclear. That can make it hard for doctors to find small problems early. This is where Artificial Intelligence (AI) tools are making a big difference. These AI Tools can check images like MRI and CT scans in real-time and make sure the quality is good before the patient even leaves the room. AI tools are now being used in many hospitals to help doctors catch issues faster, avoid repeat scans, and follow global quality standards. Whether it's a chest CT or a prostate MRI, AI makes the scanning process smoother and more accurate. One such tool is AI‑QUAL by Quibim, a Spanish health-tech company. It checks prostate MRI images and tells the radiologist if the scan meets global quality rules. This means better care for patients, less waiting, and more confidence in the results. What is AI‑QUAL? AI‑QUAL is a smart tool that helps doctors check the quality of prostate MRI scans. It works like an assistant that looks at the images and makes sure they are clear and correct. If something is missing or blurry, it gives a quick warning so the team can fix it right away. This tool was made by Quibim, a health-tech company based in Spain. They added AI‑QUAL to their special platform called QP‑Prostate, which is already used for prostate imaging. The goal is to help doctors get the best possible images, without wasting time or asking patients to come back for another scan. AI‑QUAL follows a global quality rule called PI‑QUAL version 2. This rule tells doctors what a good prostate MRI should look like. By using AI‑QUAL, hospitals and clinics can follow these standards easily and give patients faster, more reliable results. How AI‑QUAL Works AI‑QUAL works quietly in the background during prostate MRI scans. As the images are taken, the tool checks them one by one. It looks for small problems—like missing angles, unclear spots, or wrong settings. If something isn't right, it sends an alert to the radiology team right away. The smart part? It uses a system called PI‑QUAL v2, which is a global guideline for prostate MRI quality. This means AI‑QUAL knows exactly what a good scan should include. Doctors don't have to guess—they get quick, automatic feedback during the scan itself. That saves time and helps avoid repeat scans later. AI‑QUAL is fully built into Quibim's QP‑Prostate platform, so it fits smoothly into the daily work of hospitals and clinics. Instead of slowing things down, it makes the process faster and more reliable. In short, it acts like an extra pair of expert eyes—always on, always checking, always ready to help. Key Benefits for Users 1. Doctors and Radiology Teams Fast, automatic checks. AI-QUAL scores each prostate MRI in seconds, so doctors spot low-quality images right away. AI-QUAL scores each prostate MRI in seconds, so doctors spot low-quality images right away. Fewer blind spots. The tool flags common issues—like metal streaks or gas bubbles—that can hide tumors. The tool flags common issues—like metal streaks or gas bubbles—that can hide tumors. Clear next steps. A simple 'pass / retake' alert guides technologists to fix problems on the spot. No guessing, no long wait. A simple 'pass / retake' alert guides technologists to fix problems on the spot. No guessing, no long wait. More confidence. Radiologists start reading with sharper scans, which helps them trust their findings and report faster. Quick check: When was the last time your team lost minutes debating scan quality? AI-QUAL makes that question disappear. 2. Patients and Families One visit, one scan. Good images the first time mean fewer callbacks and less travel. Good images the first time mean fewer callbacks and less travel. Earlier answers. Clear pictures let doctors see small cancers sooner, which can lead to quicker treatment. Clear pictures let doctors see small cancers sooner, which can lead to quicker treatment. Lower stress. No extra appointments, no extra prep—just a smoother experience from start to finish. 3. Hospitals and Clinics Standardized quality. AI-QUAL follows the PI-QUAL v2 rules, so every scan meets the same global benchmark. AI-QUAL follows the PI-QUAL v2 rules, so every scan meets the same global benchmark. Time saved. Automated scoring removes manual checks and frees staff for patient care. Automated scoring removes manual checks and frees staff for patient care. Better workflow. Fewer retakes keep MRI rooms moving and improve daily throughput. Fewer retakes keep MRI rooms moving and improve daily throughput. Reputation boost. Consistent, high-quality imaging builds trust with referring doctors and patients alike. 4. Health Systems & Researchers Reliable data. Consistent images make clinical trials cleaner and AI training sets stronger. Consistent images make clinical trials cleaner and AI training sets stronger. Cost control. Cutting unnecessary repeat scans reduces energy use, staff time, and overall imaging costs. Use Cases & Real-Life Examples 1. Busy Hospitals with High MRI Volume In many large hospitals, radiology teams handle dozens of MRI scans every day. Sometimes, due to time pressure, a low-quality scan slips through. With AI‑QUAL, that changes. For example, if a technician misses an important view during a prostate scan, the tool immediately detects it and asks for a retake—before the patient leaves the room. This saves time, avoids rescheduling, and speeds up diagnosis. 2. Small Clinics with New Staff Smaller clinics or centers with new MRI staff often face training challenges. AI‑QUAL acts like a helpful coach. It checks every scan and gives instant feedback. This means even junior technicians can follow best practices and deliver high-quality images, right from day one. It helps build confidence and maintain professional standards. 3. Research Centers and Clinical Trials Medical researchers rely on clean, consistent images when studying new treatments or testing new technologies. If one scan in a clinical trial is blurry or incomplete, it could affect the results. That's why some research hospitals are using AI‑QUAL to make sure every scan meets the same quality level. This makes the data more trustworthy and easier to analyze. Disadvantages and Limitations of AI‑QUAL While AI‑QUAL is a helpful tool, it's not perfect. Like any new technology, it comes with a few challenges that clinics and hospitals should keep in mind. 1. It doesn't replace human judgment AI‑QUAL checks image quality, not medical results. It won't spot cancer or give a diagnosis. Doctors still need to review each scan carefully. Over-relying on AI might cause people to skip important double-checks. 2. Works only with prostate MRI Right now, AI‑QUAL is designed just for prostate MRI scans. That means it doesn't help with other types of imaging like chest CTs, brain MRIs, or full-body scans. Clinics must use different tools for other exams. 3. Needs proper setup To use AI‑QUAL, you need Quibim's QP‑Prostate platform. This could mean new software installation, staff training, and possible updates to your current systems. Smaller clinics may find this a bit tricky or costly at first. 4. May not detect all issues While AI‑QUAL follows global quality rules, it still depends on the data it was trained on. In rare cases, it might miss unusual problems or give false alerts. That's why human review is always important. Expected Trends in the Future AI‑QUAL is a strong first step, but it's just the beginning. The future of this technology looks promising, with some exciting improvements likely coming soon. 1. Expanding Beyond Prostate MRI Right now, AI‑QUAL only works with prostate MRI scans. In the future, we may see Quibim expand this tool to cover other body parts—like brain, spine or liver MRIs. That would make the technology more useful across different departments in hospitals and imaging centers. 2. Smarter Feedback with Real-Time Guidance Today, AI‑QUAL checks the image and tells if it's good or not. But soon, it might also guide the technician step-by-step during the scan. For example, it could say: 'Tilt slightly left' or 'Scan missed the top area'—making scans better without needing a retake. 3. Combining AI-QUAL with Diagnosis Tools In the future, AI‑QUAL might work alongside tools that don't just check image quality but also help detect tumors or disease signs right away. Imagine one smart system that says, 'Image looks good and here's something the doctor should see.' 4. Easier Use in Small Clinics As AI‑QUAL improves, it could become easier to install, cheaper to run, and more user-friendly for small clinics with fewer staff. This would help more communities benefit from high-quality imaging. 5. Better Reporting and Learning Future versions may come with dashboards showing scan quality trends over time. This can help hospitals train staff better, improve equipment use, and even reduce costs by avoiding repeat scans. Conclusion AI‑QUAL by Quibim is a big step forward in making prostate MRI scans more reliable. It uses smart technology to check image quality in real-time, helping doctors get clearer pictures and make better decisions. For patients, this means fewer repeat scans, faster results, and more peace of mind. While it has a few limits like working only with prostate MRI for now, its future looks bright. With time, we may see tools like AI‑QUAL used across more types of scans and in more hospitals, big and small. As medical imaging continues to grow, AI‑QUAL is leading the way toward a smarter, faster, and more accurate healthcare system. FAQs about AI-QUAL Here is the list of Frequently asked questions related to this amazing AI Tool: 1. How much does AI‑QUAL cost for a hospital or clinic? The exact cost of AI‑QUAL isn't listed online. Pricing usually depends on how many scans the hospital does and how big the imaging team is. Most AI tools like this charge either a yearly fee or a price per scan. Hospitals and clinics need to contact Quibim directly to get a custom quote based on their needs. 2. Is AI‑QUAL approved by medical authorities like the FDA? Yes. AI‑QUAL is part of Quibim's QP‑Prostate platform, which has received FDA 510(k) clearance in the U.S., CE marking in Europe, and UKCA approval in the UK. That means it's already allowed for clinical use in many countries. Still, every hospital should double-check with local health regulators before using the tool. 3. How accurate is AI‑QUAL compared to human radiologists? AI‑QUAL doesn't diagnose cancer—it only checks if the MRI image is clear and complete. It gives a score based on international standards (called PI‑QUAL v2). So far, there's no public data showing how well it performs compared to radiologists. Doctors still need to review all images, just like before. 4. Will it work with any MRI machine? Yes, in most cases. AI‑QUAL works with standard DICOM images, which are used by all major MRI machine brands. However, Quibim recommends doing a quick check during setup to make sure everything connects smoothly. 5. How long does it take to train staff? Training doesn't take long. Most technologists can learn the basics in half a day, and radiologists often get comfortable with it after just one session. If your hospital uses a custom setup, you might need a little extra time for staff orientation. 6. What happens to patient data and privacy? AI‑QUAL is designed with privacy and security in mind. It uses encrypted data and follows rules like HIPAA in the U.S. and GDPR in Europe. Patient images stay inside the hospital's system or a secure cloud. Only the quality score is shared on the screen where doctors read the scan. 7. Can AI‑QUAL be used for children? No. AI‑QUAL is built for adult prostate MRI scans only. It's not tested or approved for children. Pediatric imaging needs different tools and guidelines. 8. How does it handle tricky cases like metal implants? AI‑QUAL can detect issues like metal streaks, motion blur, or gas bubbles—things that can make images unclear. When it finds these problems, it asks for a quick retake of the scan. But doctors still decide if the new images are good enough. 9. Does it need an internet connection to work? Not always. AI‑QUAL runs locally at the hospital, so it can work even without the internet. But to get software updates and support from Quibim, it's helpful to have occasional internet access. 10. How often does it need updates or support? Like most software, AI‑QUAL gets updates for security and new features. Updates usually come every few months and can install automatically. Most hospitals also get a support contract when they buy the license, which covers help and maintenance. TIME BUSINESS NEWS
Yahoo
26-05-2025
- Business
- Yahoo
Digital Twins in Healthcare Market Research and Forecast Report 2025-2030: Europe Emerges as Key Player in Digital Twin Healthcare Market, Second to North America
The global digital twin healthcare market is set for remarkable growth, projected to soar from USD 4.47 billion in 2025 to USD 59.94 billion by 2030, at a CAGR of 68.0%. The surge is fueled by the expanding applications of digital twins in healthcare and increased investments from public and private sectors. Quibim, a Valencia-based pioneer using imaging biomarkers for precision medicine, recently raised USD 50.6 million in Series A funding to expand into the U.S. Market leaders like Microsoft, Siemens Healthineers, and GE Healthcare are advancing the sector. Notably, surgical planning & medical education, driven by virtual reality integration, captures the largest market share. Europe emerges as a key region, with substantial technological investments. The report offers a detailed analysis of market trends, competitive dynamics, and opportunities for growth in digital twin technology. Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Digital Twins in Healthcare Market by Component (Software, Services), Application (Personalized Medicine, Drug Discovery, Medical Education, Workflow Optimization), End User (Providers, Research & Academia, Payers), and Region - Global Forecast to 2030" has been added to offering. The global digital twin healthcare market is poised for remarkable growth in 2024, driven by the expanding applications of digital twins and substantial investments from both public and private sectors. The market is expected to surge to USD 59.94 billion by 2030 from USD 4.47 billion in 2025, reflecting a CAGR of 68.0% during this period. Public and private sectors are keenly investing in digital twin technologies, recognizing their potential to revolutionize innovation and boost operational efficiency. Valencia-based Quibim is a leader in leveraging imaging biomarkers for precision medicine. Recently, Quibim secured USD 50.6 million in a Series A funding round aimed at establishing a foothold in the United States. This strategic move is seen as pivotal in advancing human digital twins, dynamic models that aid health monitoring, enhance patient stratification, increase drug development success rates, and enable pre-implementation treatment testing. By application, the surgical planning & medical education segment claimed the largest market share in 2024. The dominance of this segment is attributed to the fusion of digital twins with virtual reality platforms, significantly enhancing surgical training for residents. This technology allows for simulations tailored to individual patients' unique anatomical and physiological attributes, offering trainees a realistic experience and performance tracking through intraoperative metrics. Several companies have developed medical anatomy and surgical procedure simulations to reduce cadaver dependence and promote interactive learning. By end user, the healthcare providers segment commanded the largest market share in 2024. This segment's growth is linked to its critical role in workflow management and surgical planning. Digital twins provide benefits such as accurate patient modeling, personalized treatment planning, and continuous monitoring, all of which improve clinical decision-making and patient outcomes. Europe secured the second-largest market share in 2024 by region. This is due to increased technological investments and the application of digital twins in research and genomics. The European Institute of Innovation & Technology (EIT) Health Germany reports that digital twins are being employed across European nations to enhance medication prescriptions. French firm ExactCure specializes in digital health, focusing on preventing adverse drug effects. DigiTwins utilizes advanced omics, sensing, computing, and communication technologies, enabling completely personalized and preventive medicine, heralding a significant paradigm shift in healthcare. This report provides insights on: Drivers such as burgeoning investments in developed and emerging technology adoption, rising demand for personalized medicine, and increased funding and investment in digital twin startups. Restraints include concerns over accuracy and privacy in digital twin systems and high implementation costs. Opportunities and challenges are also examined. Product/Service Development & Innovation: Detailed insights into upcoming technologies, R&D activities, and new product and service launches. Market Development: Comprehensive data on lucrative emerging markets by type, component, application, end user, and region. Market Diversification: Information about product portfolios, expanding geographic reach, recent developments, and investments. Competitive Assessment: Thorough analysis of market shares, growth strategies, product offerings, and capabilities of leading players. Market Dynamics Market Drivers Increasing Investments by Public and Private Entities Growing Applications of Digital Twins Technological Advancements Growing Funding and Investments in Digital Twin Startups Challenges Lack of Skilled Professionals Integration With Existing Systems and Outdated Digital Infrastructure Industry Trends Transformation in Clinical Trials Revolutionizing Medical Training and Diagnostics Improving Operational Efficiency in Hospitals Opportunities Increasing Focus on Cutting-Edge Real-Time Data Analytics Growing Importance of Digital Twins in Emerging Economies Case Studies Utilization of Digital Twin Technology For Surge Planning Decisions Provision of Hospital Guidance Using Digital Twins in Healthcare During COVID-19 Pandemic Optimization of Cardiovascular Solutions For Personalized Treatments Company Profiles Microsoft Corporation Siemens Healthineers Ag Koninklijke Philips N.V. Amazon Web Services, Inc. Dassault Systemes Ge Healthcare Oracle Corporation IBM Ptc Sap Atos Se Nvidia Corporation Ansys Inc. Faststream Technologies Rescale, Inc. Twin Health Verto Qbio Thoughtwire Sim and Cure Predictiv Nurea Inc. Virtonomy Gmbh Predisurge For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
